Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

T-DM1 Approved for HER2-Positive Metastatic Breast Cancer

February 22nd 2013

The FDA has approved ado-trastuzumab emtansine, also known as T-DM1, for HER2-positive metastatic breast cancer.

The Cost-Effectiveness of Targeted Therapies in NSCLC

February 13th 2013

Impact of EGFR Mutations on Treatment Decisions in NSCLC

February 13th 2013

Access to Molecular Testing Therapy in NSCLC

February 13th 2013

Personalizing the Treatment of Lung Cancer

February 13th 2013

Promising Emerging Classes of Therapies in NSCLC

February 13th 2013

Molecular Heterogeneity in Non-Small Cell Lung Cancer

February 13th 2013

Selecting Treatment for First- Line Non-Squamous NSCLC

February 13th 2013

Selecting a Laboratory for Molecular Testing in NSCLC

February 13th 2013

Rebiopsying and Molecular Testing in NSCLC

February 13th 2013

Molecular Testing and Actionable Targets in NSCLC

February 13th 2013

Best Practices in NSCLC Molecular Testing, Part II

February 13th 2013

Concurrent Versus Sequential Testing in NSCLC

February 13th 2013

Best Practices in NSCLC Molecular Testing, Part I

February 13th 2013

Introduction: Advances and Issues in NSCLC

February 13th 2013

Squamous Cell Carcinoma Treatment Options

February 13th 2013

FDA Gives Radium-223 Priority Review Status

February 13th 2013

Radium Ra 223 Dichloride will be considered as a treatment for patients who have castration-resistant prostate cancer with bone metastases under the FDA's priority review program.

Ibrutinib Receives Breakthrough Designations for Mantle Cell Lymphoma and WaldenstrÃ¶m's Macroglobulinemia

February 13th 2013

The investigational agent ibrutinib was granted "Breakthrough Therapy Designations" by the FDA as a singular therapy for a pair of B-cell malignancies: relapsed or refractory mantle cell lymphoma and WaldenstrÃ¶m's macroglobulinemia.

Pomalidomide Approved for Relapsed or Refractory Multiple Myeloma

February 8th 2013

The FDA announced the approval of pomalidomide for the treatment of multiple myeloma after patients have relapsed or become refractory to other cancer drugs.

Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost Implications

February 7th 2013

There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.